Mongoose Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mongoose Bio is a private, early-stage clinical company spun out of MD Anderson Cancer Center in 2023, based on foundational research by Dr. Cassian Yee. The company's core innovation is an epigenetic reprogramming platform that engineers long-lived central memory T cells (Tcm) with defined TCRs against validated, highly immunogenic tumor targets to treat solid tumors. Led by an experienced CEO with a track record in cell therapy and biopharma, Mongoose Bio is positioned to address the significant unmet need in solid tumor oncology by aiming to improve the persistence, safety, and efficacy profile of adoptive T cell therapies. The company is pre-revenue and focused on advancing its proprietary platform and pipeline through clinical development.

OncologySolid Tumors

Technology Platform

Proprietary epigenetic reprogramming platform to engineer autologous central memory T cells (Tcm) with defined T cell receptors (TCRs) against validated, highly immunogenic tumor-specific antigens, aiming to create persistent and active TCR-T cell therapies for solid tumors.

Opportunities

The massive, unmet need in solid tumor therapy represents a multi-hundred billion dollar market where current cell therapies have largely failed.

Mongoose Bio's platform, if clinically validated, could enable safer, more persistent, and broadly applicable treatments, positioning it as a leader in the next generation of oncology cell therapy.

The technology also allows for targeting intracellular antigens and facilitates outpatient and combination treatment strategies.

Risk Factors

The company faces high scientific risk as its core epigenetic reprogramming approach for TCR-Tcm cells is novel and unproven in human trials.

It operates in an intensely competitive landscape against well-funded rivals pursuing various cell therapy modalities for solid tumors.

As a pre-revenue, private company, it is also subject to significant financial and execution risks related to capital raising, complex manufacturing, and clinical development.

Competitive Landscape

Mongoose Bio competes in the solid tumor cell therapy space against companies developing next-generation CAR-Ts (e.g., with armored constructs), TCR-T therapies (e.g., Adaptimmune, Immunocore), TIL therapies (e.g., Iovance Biotherapeutics), and other novel modalities. Its key differentiators are the focus on epigenetic reprogramming of central memory T cells (Tcm) for enhanced persistence and its portfolio of novel, highly immunogenic TCR targets.

More companies in Cell & Gene Therapy →More companies in United States →